Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates

Table 3 Immune marker staining states among the evaluated samples

Immune marker(s)	N (%)	Immune marker(s)	N (%)
PD-1		PD-1 and TC PD-L1
Negative	303 (83.9)	Either one or both negative	292 (80.9)
Positive	27 (7.5)	Both Positive	3 (0.8)
Missing	31 (8.6)	Missing	66 (18.3)
TC PD-L1		PD-1 and LAG-3
Negative	294 (81.4)	Either one or both negative	269 (74.5)
Positive	32 (8.9)	Both Positive	16 (4.4)
Missing	35 (9.7)	Missing	76 (21.1)
IC PD-L1		IC PD-L1 and LAG-3
Negative	197 (54.6)	Either one or both negative	206 (57.1)
Positive	130 (36.0)	Both Positive	88 (24.4)
Missing	34 (9.4)	Missing	67 (18.6)
LAG-3		IC PD-L1 and TC PD-L1
Negative	126 (34.9)	Either one or both negative	303 (83.9)
Positive	184 (51.0)	Both Positive	23 (6.4)
Missing	51 (14.1)	Missing	35 (9.7)
PD-1 and IC PD-L1		PD-1, IC PD-L1, and LAG-3
Either one or both negative	284 (78.7)	One, two, or three negative	261 (72.3)
Both Positive	12 (3.3)	All Positive	8 (2.2)
Missing	65 (18)	Missing	92 (25.5)

PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; TC, tumoral cells; IC, immune cell; LAG-3, lymphocyte activation gene-3

ISSN: 1471-2407